Guoyu Hu
Zhuzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study.
Journal: Annals of hematology
Published: September 09, 2025
Impact of platelet endothelial aggregation receptor 1 genotypes and DNA methylation on platelet reactivity in patients with recurrent ischemic stroke treated with clopidogrel.
Journal: Archives of medical science : AMS
Published: October 04, 2022
A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Journal: Frontiers in oncology
Published: May 15, 2022
Diagnosis and treatment of multiple myeloma in Hunan Province.
Journal: Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
Published: May 11, 2022
A novel germline HAVCR2 (TIM-3) compound heterozygous mutation is related to hemophagocytic lymphohistiocytic syndrome in EBV-positive peripheral T-cell lymphoma (NOS) with down-regulated TIM-3 signaling.
Journal: Frontiers in oncology
Published: February 07, 2022
CHST15 gene germline mutation is associated with the development of familial myeloproliferative neoplasms and higher transformation risk.
Journal: Cell death & disease
Published: January 10, 2022
Breakpoint mapping of a t(9;22;12) chronic myeloid leukaemia patient with e14a3 BCR-ABL1 transcript using Nanopore sequencing.
Journal: The journal of gene medicine
Published: July 15, 2020
A drug targeting 5-lipoxygenase enhances the activity of a JAK2 inhibitor in CD34+ bone marrow cells from patients with JAK2V617F-positive polycythemia vera in vitro.
Journal: Oncology letters
Published: July 08, 2020
A small molecular compound CC1007 induces cross-lineage differentiation by inhibiting HDAC7 expression and HDAC7/MEF2C interaction in BCR-ABL1- pre-B-ALL.
Journal: Cell death & disease
Published: March 22, 2020
Neoantigen-activated haploidentical T cell therapy for angioimmunoblastic T-cell lymphoma.
Journal: Clinical immunology (Orlando, Fla.)
Published: December 06, 2018
RNF8 is responsible for ATRA resistance in variant acute promyelocytic leukemia with GTF2I/RARA fusion, and inhibition of the ubiquitin-proteasome pathway contributes to the reversion of ATRA resistance.
Journal: Cancer cell international
Published: December 05, 2018
Last Updated: 09/26/2026